International journal of radiation oncology, biology, physics
-
Int. J. Radiat. Oncol. Biol. Phys. · Nov 2006
Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up.
To report the incidence of second bladder and colorectal cancers after prostate brachytherapy. ⋯ There may be an increased but small risk of developing a second malignancy after radiation therapy for prostate cancer. This outcome could be related to radiation carcinogenesis, but more vigilant screening and thorough workup as a result of radiation side effects and predisposing conditions (e.g., genetic and environmental factors) in many of the patients found to have second malignancies likely contributed to the higher number of observed malignancies than expected.
-
Int. J. Radiat. Oncol. Biol. Phys. · Nov 2006
Computer optimization of noncoplanar beam setups improves stereotactic treatment of liver tumors.
To investigate whether computer-optimized fully noncoplanar beam setups may improve treatment plans for the stereotactic treatment of liver tumors. ⋯ The use of automatically generated, fully noncoplanar beam setups results in plans that are favorable compared with coplanar techniques. Because of the automation, we found that the planning workload can be decreased from 1 to 2 days to 1 to 2 h.
-
Int. J. Radiat. Oncol. Biol. Phys. · Oct 2006
Comparative StudyFive-year prospective patient evaluation of bladder and bowel symptoms after dose-escalated radiotherapy for prostate cancer with the BeamCath technique.
Late side effects were prospectively evaluated up to 5 years after dose-escalated external beam radiotherapy (EBRT) and were compared with a previously treated series with conventional conformal technique. ⋯ Dose-escalated EBRT with the BeamCath technique with doses up to 78 Gy is tolerable, and the toxicity profile is similar to that observed with conventional doses<71 Gy.
-
Int. J. Radiat. Oncol. Biol. Phys. · Oct 2006
Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy.
To compare the ability of positron emission tomography (PET) to predict response to temozolomide vs. temozolomide plus radiotherapy. ⋯ Early changes in MRGlu predict response to temozolomide, but not temozolomide plus radiotherapy.
-
Int. J. Radiat. Oncol. Biol. Phys. · Oct 2006
Randomized Controlled TrialA randomized, double-blind, placebo-controlled, cross-over study to assess the efficacy of tadalafil (Cialis) in the treatment of erectile dysfunction following three-dimensional conformal external-beam radiotherapy for prostatic carcinoma.
Erectile dysfunction after three-dimensional conformal external-beam radiotherapy (3DCRT) for prostatic carcinoma is reported in as many as 64% of those patients. The purpose of this study was to determine the efficacy of the oral drug tadalafil (Cialis) in patients with erectile dysfunction after radiotherapy for prostatic carcinoma. ⋯ Tadalafil is an effective treatment for erectile dysfunction after 3DCRT for prostatic carcinoma with successful intercourse reported in almost 50% of the patients, and it is well tolerated.